|
1.
|
Kim N, He N, Kim C, et al: Systematic
analysis of genotype-specific drug responses in cancer. Int J
Cancer. 131:2456–2464. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Bussey KJ, Chin K, Lababidi S, et al:
Integrating data on DNA copy number with gene expression levels and
drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther.
5:853–867. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Barretina J, Caponigro G, Stransky N, et
al: The Cancer Cell Line Encyclopedia enables predictive modelling
of anticancer drug sensitivity. Nature. 483:603–607. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Park ES, Rabinovsky R, Carey M, et al:
Integrative analysis of proteomic signatures, mutations, and drug
responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther.
9:257–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Lamb J: The Connectivity Map: a new tool
for biomedical research. Nat Rev Cancer. 7:54–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Shoemaker RH, Monks A, Alley MC, et al:
Development of human tumor cell line panels for use in
disease-oriented drug screening. Prog Clin Biol Res. 276:265–286.
1988.PubMed/NCBI
|
|
7.
|
Greshock J, Bachman KE, Degenhardt YY, et
al: Molecular target class is predictive of in vitro response
profile. Cancer Res. 70:3677–3686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Bignell GR, Huang J, Greshock J, et al:
High-resolution analysis of DNA copy number using oligonucleotide
microarrays. Genome Res. 14:287–295. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Zhao X, Weir BA, LaFramboise T, et al:
Homozygous deletions and chromosome amplifications in human lung
carcinomas revealed by single nucleotide polymorphism array
analysis. Cancer Res. 65:5561–5570. 2005. View Article : Google Scholar
|
|
10.
|
Forbes SA, Bindal N, Bamford S, et al:
COSMIC: mining complete cancer genomes in the Catalogue of Somatic
Mutations in Cancer. Nucleic Acids Res. 39:D945–D950. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Weir BA, Woo MS, Getz G, et al:
Characterizing the cancer genome in lung adenocarcinoma. Nature.
450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Mullighan CG, Goorha S, Radtke I, et al:
Genome-wide analysis of genetic alterations in acute lymphoblastic
leukaemia. Nature. 446:758–764. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Garraway LA, Widlund HR, Rubin MA, et al:
Integrative genomic analyses identify MITF as a lineage survival
oncogene amplified in malignant melanoma. Nature. 436:117–122.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Savas S, Briollais L, Ibrahim-zada I, et
al: A whole-genome SNP association study of NCI60 cell line panel
indicates a role of Ca2+ signaling in selenium
resistance. PLoS One. 5:e126012010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Rantala JK, Edgren H, Lehtinen L, et al:
Integrative functional genomics analysis of sustained polyploidy
phenotypes in breast cancer cells identifies an oncogenic profile
for GINS2. Neoplasia. 12:877–888. 2010.PubMed/NCBI
|
|
16.
|
Cheung HW, Cowley GS, Weir BA, et al:
Systematic investigation of genetic vulnerabilities across cancer
cell lines reveals lineage-specific dependencies in ovarian cancer.
Proc Natl Acad Sci USA. 108:12372–12377. 2011. View Article : Google Scholar
|
|
17.
|
Abaan OD, Polley EC, Davis SR, et al: The
exomes of the NCI-60 panel: a genomic resource for cancer biology
and systems pharmacology. Cancer Res. 73:4372–4382. 2013.PubMed/NCBI
|
|
18.
|
Scherf U, Ross DT, Waltham M, et al: A
gene expression database for the molecular pharmacology of cancer.
Nat Genet. 24:236–244. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ross DT, Scherf U, Eisen MB, et al:
Systematic variation in gene expression patterns in human cancer
cell lines. Nat Genet. 24:227–235. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Dan S, Tsunoda T, Kitahara O, et al: An
integrated database of chemosensitivity to 55 anticancer drugs and
gene expression profiles of 39 human cancer cell lines. Cancer Res.
62:1139–1147. 2002.PubMed/NCBI
|
|
21.
|
Spurrier B, Ramalingam S and Nishizuka S:
Reverse-phase protein lysate microarrays for cell signaling
analysis. Nat Protoc. 3:1796–1808. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zubrod CG: Origins and development of
chemotherapy research at the National Cancer Institute. Cancer
Treat Rep. 68:9–19. 1984.PubMed/NCBI
|
|
23.
|
Paull KD, Shoemaker RH, Hodes L, et al:
Display and analysis of patterns of differential activity of drugs
against human tumor cell lines: development of mean graph and
COMPARE algorithm. J Natl Cancer Inst. 81:1088–1092. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Deeken JF, Robey RW, Shukla S, et al:
Identification of compounds that correlate with ABCG2 transporter
function in the National Cancer Institute Anticancer Drug Screen.
Mol Pharmacol. 76:946–956. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
McDermott U, Sharma SV, Dowell L, et al:
Identification of genotype-correlated sensitivity to selective
kinase inhibitors by using high-throughput tumor cell line
profiling. Proc Natl Acad Sci USA. 104:19936–19941. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Karaman MW, Herrgard S, Treiber DK, et al:
A quantitative analysis of kinase inhibitor selectivity. Nat
Biotechnol. 26:127–132. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Garnett MJ, Edelman EJ, Heidorn SJ, et al:
Systematic identification of genomic markers of drug sensitivity in
cancer cells. Nature. 483:570–575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
He N, Wang X, Kim N, Lim JS and Yoon S: 3D
shape-based analysis of cell line-specific compound response in
cancers. J Mol Graph Model. 43:41–46. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Ma Q and Lu AY: Pharmacogenetics,
pharmacogenomics, and individualized medicine. Pharmacol Rev.
63:437–459. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Comprehensive molecular characterization
of clear cell renal cell carcinoma. Nature. 499:43–49. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Zeeberg BR, Kohn KW, Kahn A, et al:
Concordance of gene expression and functional correlation patterns
across the NCI-60 cell lines and the Cancer Genome Atlas
glioblastoma samples. PLoS One. 7:e400622012. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Prahallad A, Sun C, Huang S, et al:
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through
feedback activation of EGFR. Nature. 483:100–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Corcoran RB, Cheng KA, Hata AN, et al:
Synthetic lethal interaction of combined BCL-XL and MEK inhibition
promotes tumor regressions in KRAS mutant cancer models. Cancer
Cell. 23:121–128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Lu Y, Muller M, Smith D, et al: Kinome
siRNA-phosphoproteomic screen identifies networks regulating AKT
signaling. Oncogene. 30:4567–4577. 2011. View Article : Google Scholar : PubMed/NCBI
|
